ThomasPovsicMD

Interventional Cardiology, Clinical Pharmacology

Professor, Medicine, Duke Clinical Research Institute, Duke University School of Medicine

Dr. Povsic is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

9 citations
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.
Thomas J Povsic, Serge Korjian, M Cecilia Bahit, Gerald Chi, Danielle Duffy
Journal of the American College of Cardiology. 2024-06-04
24 citations
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
C Michael Gibson, Danielle Duffy, Serge Korjian, M Cecilia Bahit, Gerald Chi
The New England Journal of Medicine. 2024-05-02
1 citations
Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial.
Kenta Nakamura, Timothy D Henry, Jay H Traverse, David A Latter, Nahush A Mokadam
Circulation. Cardiovascular Interventions. 2024-05-01

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial IschemiaOctober 21st, 2021
$XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina$
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory AnginaJuly 27th, 2021
$Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get It$
Access Denied: Stem Cell Therapy Shows Some Promise in Refractory Angina, but Patients Can’t Get ItMay 19th, 2017
Join now to see all